Which renal‑safe imaging study should be used to evaluate an elevated AFP (alpha‑fetoprotein) level in a patient with impaired renal function (creatinine 1.41 mg/dL, eGFR (estimated glomerular filtration rate) 57 mL/min/1.73 m²)?

Ultrasound is the Imaging Modality of Choice

For an elevated AFP (alpha-fetoprotein) of 12 in a patient with Stage 3a CKD (creatinine 1.41, eGFR 57), ultrasound should be the primary imaging modality because it avoids nephrotoxic contrast agents while providing essential diagnostic information about liver and abdominal pathology.

Rationale for Ultrasound

Your patient has Stage 3a chronic kidney disease (eGFR 57 mL/min/1.73 m²), which represents moderate renal impairment 1. While this level of renal function doesn't absolutely prohibit contrast-enhanced imaging, ultrasound offers several advantages:

• No nephrotoxicity risk: Ultrasound contrast agents are not nephrotoxic, making them ideal for patients with any degree of renal impairment 1
• Adequate for initial evaluation: Ultrasound effectively evaluates hepatic masses, cirrhosis, and other causes of elevated AFP
• Provides structural information: Can assess kidney size, echogenicity, and rule out obstruction 2, 3

When MRI May Be Considered

If ultrasound findings are indeterminate or additional characterization is needed:

MRI with Group II gadolinium-based contrast agents (macrocyclic agents) can be safely used at eGFR 57 mL/min/1.73 m² 4. The ACR-NKF consensus specifically addresses that:

• Group II GBCM carry extremely low risk of nephrogenic systemic fibrosis
• The threshold for concern is primarily eGFR <30 mL/min/1.73 m²
• At eGFR 57, the benefits of diagnostic MRI typically outweigh minimal risks 4

Alternatively, non-contrast MRI techniques can evaluate renal and hepatic pathology without any contrast exposure 5, 6.

Avoid CT with Iodinated Contrast

While not absolutely contraindicated at eGFR 57, iodinated contrast for CT carries risk of contrast-induced nephropathy and should be reserved for situations where ultrasound and MRI cannot answer the clinical question 1, 7.

Clinical Algorithm

1. Start with ultrasound of abdomen/liver to evaluate AFP elevation
2. If ultrasound is diagnostic: proceed with appropriate management
3. If ultrasound is indeterminate:
   • Consider MRI with Group II GBCM (safe at this eGFR level)
   • Or non-contrast MRI techniques
4. Reserve CT with contrast only if ultrasound and MRI are unavailable or non-diagnostic and the clinical question is urgent

Important Caveat

The renal impairment itself warrants evaluation. Renal ultrasound should also be performed to assess kidney size, echogenicity, and exclude obstruction, as these findings help distinguish acute from chronic kidney disease and guide prognosis 2, 3.